Cytokinetics
Clinical trials sponsored by Cytokinetics, explained in plain language.
Biopharmaceutical company focused on muscle biology and cardiac muscle diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New heart failure drug aims to cut hospitalizations and deaths
Disease control Recruiting nowThis study tests an investigational drug called omecamtiv mecarbil in 1,800 adults with severe heart failure and a very weak heart pump. The goal is to see if it can lower the risk of heart failure worsening, hospitalization, need for a heart pump or transplant, or death. Partici…
Phase: PHASE3 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New heart failure pill shows promise in early trial
Disease control Recruiting nowThis study tests a new drug called CK-4021586 (ulacamten) in 60 adults with a type of heart failure where the heart pumps normally but is stiff (HFpEF). Participants take the drug or a placebo for 12 weeks to see if it is safe and how it affects heart function. The goal is to fin…
Phase: PHASE2 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug aims to help kids with stiff heart muscle breathe easier
Disease control Recruiting nowThis study tests a medicine called aficamten in children aged 12 to 18 with a heart condition that makes it hard for blood to pump out. The goal is to see if the drug can reduce pressure inside the heart and improve symptoms like shortness of breath. About 55 participants will re…
Phase: PHASE2, PHASE3 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC